---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210324"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:05:44.703771+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rapport Q1 net loss $19.9M, cash $476.8M; RAP-219 Phase 3 in FOS on track for Q2 2026

## Summary
- Net loss $19.9M (vs $24.1M YoY); collaboration revenue $20.0M from Tenacia deal.
- Cash $476.8M at March 31, 2026; runway into 2H 2029.
- RAP-219 Phase 3 for focal onset seizures on track to begin Q2 2026; follow-up data showed 90% median seizure reduction weeks 9-12.
- Bipolar mania Phase 2 topline results now expected Q4 2026 (ahead of prior 1H 2027 guidance).
- R&D expense $32.7M (up from $19.6M); G&A $11.5M ($7.5M); Tenacia collaboration signed March 2026.

## SEC filing metadata
- accession: 0001193125-26-210324
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/0001193125-26-210324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210324
- JSON: https://secwatch.observer/filing/0001193125-26-210324.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210324.txt

## Source-grounded claims
- claim_id: cacbe5107c153b50d60ad30442846bf7148da0a9
  claim: Rapport Therapeutics, Inc. reported financial results for the quarter ending March 31, 2026.
  evidence_excerpt: On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/0001193125-26-210324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.